Drugs / HGI-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05864170 | May 2022 → Dec 2025 overdue | beta-thalassemia major | Shenzhen Hemogen | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HGI-001 | “the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia” NCT05864170 ↗ |
| Action | Restore | “to restore β-globin expression” NCT05864170 ↗ |
| Modality | Cell therapy | “β-globin restored autologous hematopoietic stem cells” NCT05864170 ↗ |